NEW YORK — Fosun Pharmaceutical said on Thursday that its Fosun Long March Medical Science subsidiary has received emergency approval from China's National Medical Products Administration for a SARS-CoV-2 detection kit.

According to Shanghai, China-based Fosun Pharma, the kit is designed to detect the virus' ORF1ab, N, and E genes, and can proess 96 samples within two hours.

Earlier this month, Fosun Long March received CE marking for its SARS-CoV-2 nucleic acid detection kit, Fosun Pharma said.